Towards a Consensus Potency Assay for Mesenchymal Stromal Cells: A Matrix Analysis of Cell Source, Donor Variability, and Inflammatory Stimuli to Refine Surrogate Markers of Immunomodulation

    May 2019 in “ Cytotherapy ”
    Danielle M. Wiese, Barry N. Ford, Lorena R. Braid
    Studysummary In this study, only a subset of proposed biomarkers universally responded to priming in mesenchymal stromal cells, suggesting limited utility for standardized potency assays across different MSC types and conditions.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on isct-cytotherapy.org →
    Discuss this study in the Community →